NMRA experienced severe financial deterioration with stockholders' equity plummeting 64% to $104M while total liabilities nearly tripled to $87M, indicating potential liquidity stress despite increased cash position.
The dramatic erosion of stockholders' equity combined with the tripling of liabilities suggests significant dilutive financing activities or major write-downs that have severely impacted the company's financial foundation. While cash increased 28%, the overall balance sheet deterioration raises concerns about the company's ability to fund operations without further dilutive equity raises, particularly given the continued high cash burn rate of over $200M annually.
NMRA's financial position deteriorated significantly with stockholders' equity collapsing 64% to $104M while total liabilities surged 192% to $87M, suggesting major dilutive financing or significant write-downs occurred during the period. Despite cash increasing 28% to $183M, total assets declined 40% and operating cash flow worsened to -$206M, indicating the company consumed substantial resources while likely issuing equity at unfavorable terms. The combination of reduced R&D spending (-12%) with worsening cash burn suggests cost-cutting measures amid financial stress, creating a challenging backdrop for advancing their clinical programs.
Liabilities grew 191.5% — significant increase in debt or obligations, assess impact on financial flexibility.
Capex reduced 77.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 39.7% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 39.3% — monitor working capital adequacy and short-term liquidity.
Cash grew 28.4% — improving liquidity position supports investment and shareholder returns.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
R&D spending cut 12.4% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →